Valor202020212022202320242025TTMGastos comerciales, generales y administrativos3.79 B4.36 B4.52 B5.19 B5.98 B6.89 B6.89 BInvestigación y desarrollo1.14 B1.2 B1.32 B1.41 B1.61 B2.05 B2.05 BBeneficio operativo-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.61 BTotal de ingresos no operativos1 M-123 M-508 M-358 M-407 M-96 M-96 MGastos por intereses, netos de intereses capitalizados361 M341 M470 M265 M305 M349 M349 MIngresos no operativos, una vez deducidos los gastos por intereses-722 M-682 M-940 M-530 M-391 M-217 M-217 MIngresos/gastos extraordinarios362 M218 M-38 M-93 M-321 M-228 M-228 MBeneficio antes de impuestos-79 M1.08 B1.14 B1.99 B2.28 B3.38 B3.38 BParticipación en los beneficios———————Impuestos2 M36 M443 M393 M436 M493 M493 MParticipación minoritaria———1 M-8 M-6 M-6 MOtros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-82 M1.04 B698 M1.59 B1.85 B2.89 B2.89 BOperaciones suspendidas———————Beneficio neto-82 M1.04 B698 M1.59 B1.85 B2.89 B2.89 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-115 M985 M642 M1.57 B1.85 B2.9 B2.9 BBeneficio básico por acción-0.080.690.451.081.261.961.96Beneficio por acción diluido-0.080.690.451.071.251.941.94Número medio de acciones ordinarias1.42 B1.42 B1.43 B1.45 B1.47 B1.48 B5.92 BAcciones diluidas1.42 B1.43 B1.44 B1.46 B1.49 B1.49 B5.98 BEBITDA1.04 B2.29 B2.78 B3.54 B3.87 B4.98 B4.98 BEBIT-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.61 BCosto de los ingresos3.46 B3.71 B3.96 B4.34 B5.26 B6.22 B6.22 BOtros costes de producción149 M——————Amortización y depreciación (flujo de caja)1.12 B1.09 B1.14 B1.2 B1.27 B1.37 B1.37 B
Boston Scientific Corporation
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.